Free Trial
Memorial Day Savings! Save $100 on MarketBeat All Access
Claim Your Discount
Claim MarketBeat All Access Sale Promotion

Avanos Medical (AVNS) 10K Form and Latest SEC Filings 2026

Avanos Medical logo
$24.76 +0.02 (+0.06%)
Closing price 03:59 PM Eastern
Extended Trading
$24.76 0.00 (0.00%)
As of 05:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Latest Avanos Medical SEC Filings & Recent Activity

Avanos Medical (NYSE:AVNS) has submitted 358+ documents to the U.S. Securities and Exchange Commission (SEC) since 2017. For investors, these filings are the primary source of verified financial data — covering everything from annual revenue and debt levels in the 10-K, to material business events in 8-K current reports, to insider buying and selling activity in Form 4 disclosures. Key figures from these filings, including revenue, earnings, and cash flow, are summarized in Avanos Medical's financial statements. The most recent filing was a Form SCHEDULE 13G/A submitted on May 15, 2026.

Form 4
AVANOS MEDICAL, INC. Reports Ownership Change on May. 12, 2026

Form 4 filings disclose changes in stock ownership by company insiders, including purchases, sales, grants, and option exercises.

View insider ownership

8-K
Avanos Medical Files Current Report on May. 5, 2026

An 8-K is filed when a material corporate event occurs, such as an acquisition, leadership change, or financial update.

View filing

10-K
Avanos Medical Files Annual Report on Feb. 24, 2026

The 10-K contains Avanos Medical's audited financial statements, revenue, earnings, and risk factors for the prior fiscal year.

View earnings history

Avanos Medical SEC Filing History

Browse Avanos Medical's complete SEC filing history using the filters below. Filter by form type - 10-K, 10-Q, 8-K, Form 4, and more - or set a custom date range to find a filing.

DateFilerForm TypeView
05/15/2026 10:06 AM
ARMISTICE CAPITAL, LLC (1601086) Filed by
Avanos Medical (1606498) Subject
Form SCHEDULE 13G/A
05/12/2026 10:40 AM
Avanos Medical (1606498) Issuer
Franchini Indrani Lall (1708764) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/12/2026 10:41 AM
Avanos Medical (1606498) Issuer
Egbuonu-Davis Lisa (1873318) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/12/2026 10:41 AM
Avanos Medical (1606498) Issuer
BLACKFORD GARY (1156320) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/12/2026 10:35 AM
Avanos Medical (1606498) Issuer
Shimer Julie Ann (1391349) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/12/2026 10:37 AM
Avanos Medical (1606498) Issuer
OLEARY PATRICK J (1248039) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
05/07/2026 10:03 AM
Avanos Medical (1606498) Subject
T. Rowe Price Investment Management, Inc. (1897612) Filed by
Form SCHEDULE 13G/A
05/07/2026 9:32 AM
Avanos Medical (1606498) Subject
T. Rowe Price Investment Management, Inc. (1897612) Filed by
Form SCHEDULE 13G/A
05/05/2026 3:46 PM
Avanos Medical (1606498) Filer
Form DEFA14A
05/05/2026 6:00 AM
Avanos Medical (1606498) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/24/2026 1:45 PM
Avanos Medical (1606498) Issuer
Delgado Sigfrido (2023834) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/24/2026 1:46 PM
Avanos Medical (1606498) Issuer
Galovan Scott Michael (2082926) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/23/2026 12:28 PM
Avanos Medical (1606498) Filer
Form DEFA14A
04/16/2026 3:37 PM
Avanos Medical (1606498) Issuer
Pacitti David (1722733) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
04/14/2026 3:23 PM
Avanos Medical (1606498) Filer
Form DEFA14A
04/14/2026 12:59 PM
Avanos Medical (1606498) Filer
Form DEFA14A
04/14/2026 5:07 AM
Avanos Medical (1606498) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
04/01/2026 2:22 PM
Avanos Medical (1606498) Issuer
Pacitti David (1722733) Reporting
Form 4/A
04/01/2026 2:24 PM
Avanos Medical (1606498) Issuer
Galovan Scott Michael (2082926) Reporting
Form 4/A
04/01/2026 2:25 PM
Avanos Medical (1606498) Issuer
Delgado Sigfrido (2023834) Reporting
Form 4/A
04/01/2026 10:59 AM
Avanos Medical (1606498) Issuer
Delgado Sigfrido (2023834) Reporting
Form 4/A
04/01/2026 10:46 AM
Avanos Medical (1606498) Issuer
Galovan Scott Michael (2082926) Reporting
Form 4/A
04/01/2026 10:48 AM
Avanos Medical (1606498) Issuer
Pacitti David (1722733) Reporting
Form 4/A
03/26/2026 3:08 PM
Avanos Medical (1606498) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G/A
03/17/2026 4:25 PM
Avanos Medical (1606498) Issuer
Galovan Scott Michael (2082926) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/17/2026 4:26 PM
Avanos Medical (1606498) Issuer
Hurley John Joseph (1924834) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/12/2026 3:46 PM
Avanos Medical (1606498) Filer
Form ARS
03/11/2026 1:30 PM
Avanos Medical (1606498) Issuer
Galovan Scott Michael (2082926) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/11/2026 1:31 PM
Avanos Medical (1606498) Issuer
Hurley John Joseph (1924834) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/10/2026 8:48 AM
Avanos Medical (1606498) Issuer
Galovan Scott Michael (2082926) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
03/10/2026 8:49 AM
Avanos Medical (1606498) Issuer
Hurley John Joseph (1924834) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
02/26/2026 6:02 AM
Avanos Medical (1606498) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/24/2026 3:28 PM
Avanos Medical (1606498) Filer
Form 10-K
Annual report pursuant to Section 13 or 15(d)  
02/24/2026 6:02 AM
Avanos Medical (1606498) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
02/17/2026 8:52 PM
ARMISTICE CAPITAL, LLC (1601086) Filed by
Avanos Medical (1606498) Subject
Form SCHEDULE 13G/A
02/13/2026 11:11 AM
Avanos Medical (1606498) Subject
RGM Capital, LLC (1323953) Filed by
Form SCHEDULE 13G/A
01/21/2026 12:21 PM
Avanos Medical (1606498) Subject
DIMENSIONAL FUND ADVISORS LP (354204) Filed by
Form SCHEDULE 13G/A
01/13/2026 4:28 PM
Avanos Medical (1606498) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
12/05/2025 3:03 PM
Avanos Medical (1606498) Filer
Form 8-K/A
11/19/2025 12:45 PM
Avanos Medical (1606498) Issuer
Holbrook Kerr (1861246) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
11/18/2025 10:45 AM
Avanos Medical (1606498) Subject
Holbrook Kerr (1861246) Reporting
Form 144
Notice of proposed sale of securities pursuant to Rule 144  
I was right about SpaceX (Ad)

Jeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,000%. Now he says SpaceX is shaping up to be the biggest IPO of the decade - and three key milestones just confirmed it. In the past 21 days: SpaceX crossed 10,000 active satellites, Elon filed confidential IPO paperwork with the SEC, and another rocket launched 25 more satellites. Two-thirds of every satellite in orbit now belongs to one company. The public filing could drop any day.tc pixel

See how to claim your stake in SpaceX before the public can
11/14/2025 5:39 PM
ARMISTICE CAPITAL, LLC (1601086) Filed by
Avanos Medical (1606498) Subject
Form SCHEDULE 13G
11/05/2025 3:28 PM
Avanos Medical (1606498) Filer
Form 10-Q
General form for quarterly reports under Section 13 or 15(d)  
11/05/2025 6:01 AM
Avanos Medical (1606498) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/30/2025 1:26 PM
Avanos Medical (1606498) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G/A
10/23/2025 6:01 AM
Avanos Medical (1606498) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
10/09/2025 12:48 PM
Avanos Medical (1606498) Subject
DIMENSIONAL FUND ADVISORS LP (354204) Filed by
Form SCHEDULE 13G/A
10/07/2025 11:51 AM
Avanos Medical (1606498) Subject
T. Rowe Price Investment Management, Inc. (1897612) Filed by
Form SCHEDULE 13G/A
09/15/2025 6:05 AM
Avanos Medical (1606498) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
09/09/2025 11:55 AM
Avanos Medical (1606498) Issuer
Hurley John Joseph (1924834) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/22/2025 1:40 PM
Avanos Medical (1606498) Issuer
Galovan Scott Michael (2082926) Reporting
Form 3
Initial statement of beneficial ownership of securities  
08/15/2025 11:02 AM
Avanos Medical (1606498) Issuer
BLACKFORD GARY (1156320) Reporting
Form 4
Statement of changes in beneficial ownership of securities  
08/05/2025 5:49 AM
Avanos Medical (1606498) Filer
Form 8-K
Current report pursuant to Section 13 or 15(d)  
07/29/2025 10:24 AM
Avanos Medical (1606498) Subject
VANGUARD GROUP INC (102909) Filed by
Form SCHEDULE 13G/A
06/18/2025 2:41 PM
Avanos Medical (1606498) Filer
Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans  
06/02/2025 10:36 AM
Avanos Medical (1606498) Filer
Form SD
Specialized Disclosure Report  
(Data available from 1/1/2016 forward)

Avanos Medical SEC Filings - Frequently Asked Questions

Avanos Medical (AVNS) has submitted 358+ filings to the SEC since 2017. You can browse the complete history or filter by form type using the tools above.

Avanos Medical's fiscal year ends on December 31. The company typically files its 10-K annual report by the end of February, covering the prior fiscal year's financial results. Key financial data from these reports is available on Avanos Medical's financial statements page.

The most recent filing was a Form SCHEDULE 13G/A submitted on May 15, 2026. View the full filing using the link above.

SEC Filing Types: 10-K, 10-Q, 8-K and More

SEC filings are legally required disclosures that public companies submit to the U.S. Securities and Exchange Commission. Unlike press releases or earnings call transcripts, these documents are filed under legal obligation — meaning the financial data they contain is audited, standardized, and subject to penalties if materially false. For investors, that makes SEC filings the most reliable primary source available for evaluating a company's true financial position.

Yes. All SEC filings are publicly available through the SEC's EDGAR database and on financial research platforms like MarketBeat. Companies are required by law to make these disclosures accessible to all investors — meaning retail investors have access to the same source documents as institutional analysts.

A 10-K is an annual report containing audited financial statements and a full review of the company's business — it is the most comprehensive filing a company makes each year. A 10-Q is a shorter, unaudited quarterly update filed three times per year between annual reports. Investors typically use the 10-K for deep fundamental analysis and the 10-Q to track whether the company is on pace with its guidance mid-year.

The most important filing for fundamental investors. Filed once per year, the 10-K contains audited financial statements, revenue and earnings trends, debt obligations, risk factors, and management's own assessment of the business. Reading the risk factors section and comparing year-over-year financials can reveal issues that don't show up in analyst summaries.

An unaudited financial update filed three times per year (the 10-K covers Q4). Investors use 10-Qs to track whether guidance is on pace, monitor changes in cash flow or inventory, and catch any mid-year shifts in business conditions before they become headline news.

Filed within four business days of a material event — earnings releases, merger announcements, executive departures, or major asset sales. Because 8-Ks are filed before media coverage catches up, they are often the fastest way to get unfiltered information directly from the company on market-moving events.

Filed within two business days whenever an executive or director buys or sells company stock. Insider purchases — especially large or clustered buys — are often interpreted as a signal of management confidence. Insider selling is more ambiguous but worth monitoring for patterns, particularly around lock-up expirations or ahead of major announcements.


Related Companies and Tools


This page (NYSE:AVNS) was last updated on 5/19/2026 by MarketBeat.com Staff.
From Our Partners